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Diabetic retinopathy (DR) is a multifactorial microvascular disease 
induced by hyperglycemia and subsequent metabolic abnormalities. 
The resulting cell stress causes a sequela of events that ultimately can 
lead to severe vision impairment and blindness. The early stages are 
characterized by activation of glia and loss of pericytes, endothelial 
cells (EC) and neuronal cells. The integrity of the retinal 
microvasculature becomes affected, and, as a possible late response, 
macular edema may develop as a common reason for vision loss in 
patients with non-proliferative DR. Moreover, the local ischemia can 
trigger vasoproliferation leading to vision-threating proliferative DR 
(PDR) in humans. Available treatment options include control of 
metabolic and hemodynamic factors. Timely intervention of advanced 
DR stages with laser photocoagulation, intraocular anti–vascular 
endothelial growth factor (VEGF) or glucocorticoid drugs can reduce 
vision loss.  
As the pathology involves cell loss of both the vascular and neuroglial 
compartments, cell replacement strategies by stem and progenitor cells 
have gained considerable interest in the past years. Compared to other 
disease entities, so far little is known about the efficacy and potential 
mode of action of cell therapy in treatment of DR. In preclinical models 
of DR different cell types have been applied ranging from embryonic 
or induced pluripotent stem cells, hematopoietic stem cells, and 
endothelial progenitor cells to mesenchymal stromal cells (MSC). The 
latter cell population can combine various modes of action (MoA), thus 
they are among the most intensely tested cell types in cell therapy. The 
aim of this review is to discuss the rationale for using MSC as potential 





MSCs and speculate how these may support the repair of the damaged 
retina.  
Diabetic retinopathy 
DR is a complex and multifactorial diabetic complication. 
Hyperglycemia, inflammation and neuronal dysfunction are the major 
factors in the pathophysiology of DR but also systemic factors such as 
hypertension may be involved. A variety of biochemical pathways are 
affected as discussed in detail previously (Hammes, et al. 2002; 
Hammes, et al. 2011b; Stitt, et al. 2016). Especially chronic 
hyperglycemia appears as the initiator of a vicious cycle of events by 
inducing biochemical abnormalities in target tissues of diabetic 
complications through mitochondrial overproduction of reactive 
oxygen species (ROS) (Brownlee 2005). Mechanisms, which lead to 
ROS production, are at least: increased polyol pathway flux, increased 
formation of advanced glycation end products (AGEs), activation of 
protein kinase C and increased hexosamine pathway flux. The resulting 
oxidative stress induces injury to all cell types in the retina. Pericytes 
appear to be the first cell type affected, then endothelial cells vanish 
leaving nonperfused acellular capillaries (Hammes, et al. 2011a). This 
vasoregression is accompanied by neuronal damage affecting the 
neurovascular unit and the blood-retina barrier. The proliferative stage 
is caused by severe retinal ischemia, uncontrolled expression of 
proangiogenic factors and endothelial cell proliferation leading to 
severely hyperpermeable and rupture-prone vessels. Inflammatory 
processes play an important additional role. Inflammatory cytokines 
are produced by a variety of cell types under hyperglycemic and 






The disease can progress from a mild form of non-proliferative disease, 
marked by microaneurysms in the retina to severe stages, denoted by 
intraretinal hemorrhages, venous beading and intraretinal 
microvascular abnormalities (Stitt, et al. 2016) (Fig. 1). Tight glycemic 
control can significantly reduce the risk and progression of DR in early 
stages (Aiello and DCCT/EDIC Research Group 2014). In patients 
with type 1 diabetes (T1D), renin–angiotensin system inhibitors are 
now standard therapy if incipient diabetic nephropathy coincides. 
Evaluating the progression of DR in patients requires non-invasive 
methods. The first and most important method is funduscopy with and 
without permanent documentation by photography. Funduscopy 
focusses mainly on the detection of the main diabetes-related vascular 
pathologies, i.e. progressive vasoregression and increased vascular 
permeability (Williams, et al. 2004). This is complemented by optical 
coherence tomography, which enables the identification of retinal 
degeneration, of macular edema and of inflammatory cell invasion 
(Virgili, et al. 2015). Not widely used techniques like ultra-wide field 
imaging can assess important morphological changes in the peripheral 
retina and give clues on the severity of DR (Soliman, et al. 2012). 
Finally, sensitivity of cells constituting the neuroretina layer is 
measured by multifocal electroretinogram (ERG) (Harrison, et al. 
2011). Abnormality in cells’ electrical signals may precede the 
development of retinal lesions and microaneurysms in some, but not in 
all cases (Santos, et al. 2017). Furthermore, regular screening for 
clinical signs of DR helps to control disease progression and can reduce 
the risk of vision loss by enabling timely intervention with laser 
photocoagulation or intraocular drug injection (anti-VEGF or 
glucocorticoids) (DCCT/EDIC Research Group, et al. 2017). 





be only transitory, or can have adverse side effects. Therefore, the 
clinical use is limited and new treatment strategies are needed.  
The majority of established therapies target quite advanced states of 
DR. It is desirable to develop strategies which target early phases in 
DR to delay or even prevent DR. Cell-based therapies may offer direct 
tissue replacement and/or endogenous regeneration via trophic 
paracrine factors. Besides MSC, endothelial progenitor cells 
(EPC)/endothelial colony forming cells and pluripotent embryonic or 
induced pluripotent stem cells (iPSC) have been tested (Park 2016). 
Due to their broad mechanisms of action, involving secretion of trophic 
factors, similarity to pericytes, extracellular matrix (ECM) modulation, 
ROS scavenging potential and finally immune modulatory capacities, 
MSC may affect DR disease progression at different disease stages 















































































































































































































































































































































































































































Fig. 2. Proposed mechanism of action (MoA) of MSC in DR. Thick arrows indicate MoA based 
on the use of MSCs in preclinical models of DR (see also Table 2). Dotted arrows indicate known 
MoA based on diabetes studies at a systemic level, but not explicitly in DR (requires confirmation 
in (pre)clinical models). Regular arrows indicate hypothesized MoA, based on the use of MSCs in 





Animal models of DR 
Firstly, rodents represent a valuable animal model to investigate the 
impact of cell therapy in DR because of their short life cycle and 
responsiveness to genetic manipulation. Secondly, the use of 
streptozotocin (STZ), specifically toxic to β cells in the pancreas, 
induces reproducible severely hyperglycemic conditions mimicking 
essentials features of the human disease. STZ causes destruction of the 
pancreatic islet and, subsequent hypoinsulinemia and hyperglycemia  
(Rossini, et al. 1977). In the retina, early signs of DR corresponding to 
preclinical human disease stages are evident, i.e. loss of pericytes, 
vasoregression, neurodegeneration and glial activation (Hammes 
2018). There are several other animal models with different 
characteristics and dynamics, such as the Ins2Akita (Akita) mouse 
model which holds a mutation in the gene encoding insulin-2 causing 
spontaneous diabetes (Barber, et al. 2005). 
It has to be noted that the current animal models can only serve as 
models for incipient DR as none of the animals develops PDR. In order 
to obtain a mouse strain with PDR, transgenic mice, in which the 
bovine rhodopsin promoter is coupled to the gene for human VEGF, 
have been crossed with Akita mice (Okamoto, et al. 1997). The hybrid, 
named Akimba, shows several signs of PDR such as microaneurysms, 
leaky capillaries, and capillary dropout (Rakoczy, et al. 2010). Finally, 
the angiogenic aspects of PDR can be simulated by exposing mice to 
hyperoxia resulting in retinal ischaemia followed by proliferative 
vascular damage in the retina layers (oxygen-induced retinopathy 
(OIR) (Smith, et al. 1994). These are the main animal models which 





Mesenchymal stromal cells: a brief overview 
MSC were first described by Friedenstein in 1970 as fibroblast colony-
forming cells, isolated from bone marrow, with osteogenic 
differentiation potential. It is noteworthy to emphasize that 
Friedenstein himself, already at their first description, introduced them 
as new “therapeutic” component to be considered in bone marrow 
transplants (Friedenstein, et al. 1970). 
After their first description MSC were widely studied, bringing new 
insights regarding their biology and functions. Moreover, different 
sources of MSC were found beyond bone marrow (BM-MSC) such as 
adipose tissue (adipose tissue-derived stem/stromal cells - ASC) 
(Bajek, et al. 2016; Kern, et al. 2006), dental pulp (Perry, et al. 2008), 
cord blood (CB-MSC) (Bieback, et al. 2004) and Wharton´s jelly (WJ-
MSC) (Joerger-Messerli, et al. 2016). However, at the same time, 
misconceptions about MSC were arising, limiting their applicability in 
therapeutic approaches (Phinney and Sensebe 2013). The message of 
the authors is: a) MSCs differ based on their tissue origin and b) when 
isolated from different organisms, c) MSC are heterogeneous, d) the 
current panel of surface “markers” is insignificant for function, e) 
MSCs function in vitro may/will differ from their in vivo, thus f) only 
clinical data will be able to give insight into the mode of action. 
In this context, at least minimal criteria regarding MSC 
characterization were proposed by the International Society for 
Cellular Therapy (ISCT). Following ISCT guidelines, MSC are defined 
as multipotent progenitor cells with a fibroblast-like, spindle shape 
morphology and a robust proliferation capacity. They possess a strong 
plastic adherence, and trilineage mesenchymal differentiation potential 
(adipocytes, osteoblasts and chondroblasts) as well as a panel of 





the meantime, modifications of these criteria have been agreed on to 
characterize MSC from other tissue sources, e.g. ASC (Bourin, et al. 
2013). 
Table 1. Main MSCs trophic mediators 





Reported as a mitogen. Regulates 
and induce angiogenesis. Involved 








One of the key regulators of 
angiogenesis. Inhibits apoptosis. 











Positive regulation of sprouting. 
Regulation of proteins on cell 







Regulation of stem cells 








Regulates retinal cells apoptosis. 
Signal transduction. Positive 
regulation of cells proliferation. 
 
Interest in MSC as therapeutic cells has been steadily increasing, 





properties. In addition, their beneficial behavior in contexts of different 
diseases such as graft versus host disease (Le Blanc Katarina, et al. 
2004; Le Blanc Katarina, et al. 2008), wound healing processes (Gaur, 
et al. 2017; Kim, et al. 2017), tumors (Blogowski, et al. 2016; 
Cammarota and Laukkanen 2016; Koliaraki, et al. 2017), and 
autoimmune diseases (Pistoia and Raffaghello 2017; Tyndall 2008) has 
been documented. Taking into account the multiplicity of studies and 
diseases in which MSC treatment has been applied, at least three 
mechanisms can be considered predominant in the MoA of MSC in a 
diseased context. 
First and most documented MoA is represented by the paracrine and 
trophic potential. MSC, in fact, are able to secrete a broad range of 
growth factors that can modulate their surrounding microenvironment, 
favoring cell-cell interaction and communication with different cell 
types (Salgado, et al. 2010). 
Secondly, MSC retain an immunological profile that makes them hypo-
immunogenic. Because of low surface expression of HLA class I, 
inducible HLA-class II expression and the lack of costimulatory 
molecules such as CD40, CD80 and CD86 they may survive in an 
allogeneic environment (Haddad and Saldanha-Araujo 2014). In 
addition, MSC are strong immunomodulators (Najar, et al. 2016). 
Immunomodulation can be mediated by both cell-cell interaction and 
the release of soluble factors. The most reported mechanism is the 
MSC-mediated inhibition of T-cell proliferation, and the promotion of 
a regulatory T-cell subpopulation (Treg) (Haddad and Saldanha-Araujo 
2014; Luz-Crawford, et al. 2013). However, MSC can interact also 
with B-cells, natural killer cells, monocytes/macrophages and dendritic 
cells. The production of immunoregulatory factors such as TGF-β, 





and nitric oxide (NO) has been widely documented in several studies 
and directly sustains their immunological potential (Yan, et al. 2014a; 
Yang, et al. 2009). 
Lastly, MSC have a differentiation potential that is clearly related to 
their multipotency. This potency would enable them to differentiate 
towards the damaged or lost cell types in order to replace cells at least 
transiently at the site of injury. However, the understanding of the 
underlying mechanisms of homing, proliferation, differentiation and 
functional engraftment of MSCs is in its infancy, in particular with 
respect to treatment of DR. The mere fact that e.g. in rodent models for 
retinal injury, MSC co-localized with and acquired neuronal and glial 
markers (rhodopsin resp. GFAP) or pericytic markers (Rajashekhar G, 
et al. 2014 Mendel TA, et al. 2013) does confirm that the respective 
functions were acquired too after intravitreal administration. Cell 
fusion may have happened resulting in co-expression of different 
marker molecules (Park 2016; Tomita, et al. 2002). 
These combined functions render MSC one of the most interesting and 
promising tool for a potential therapeutic cell-based approach for a 
number of diseases. 
MSC for DR treatment – potential modes of action 
Given the potential of MSCs and the characteristics of early DR in 
models, the promotion of cell repair and the defense against stress cell 
damage evolves as experimental focus. The functional restoration of 
damaged tissue by repair or regeneration can be accomplished by stem 
cells in three ways or a combination. Firstly, stem cells are constructive 
via their differentiation and engraftment into tissue. Secondly, stem 
cells are instructive which means that via the secretion of trophic 





proregenerative state. Thirdly, stem cells may act in a reconstructive 
manner via the remodeling of the extracellular matrix (ECM) by 
secretion of e.g. matrix metalloproteinases (MMPs) and a host of 
structural (ECM) proteins. The reconstructive function of, in particular 
MSC, is frequently neglected, but it should be noted that the ECM is 
the prime extracellular reservoir of growth factors as well as of diabetic 
triggers for inflammation (AGEs). 
MSC as trophic mediators 
MSC are well known to secrete a broad range of pro-regenerative, 
mitotic, angiogenic, anti-apoptotic, anti-fibrotic factors, such as basic 
fibroblast growth factor (bFGF), VEGF, insulin-like growth factor 
(IGF), HGF, nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), glial-derived neurotrophic factor (GDNF), ciliary 
neurotrophic factor (CNTF) (Table 1) (Caplan 2008; Ezquer, et al. 
2014; Griffin, et al. 2016). These factors appear to modify the local 
microenvironment from an adverse injury to a pro-regenerative milieu. 
In addition to secreted growth factors, cytokines and chemokines, 
which will be influential, but most likely in local distance and short-
lived, MSC are able to pack trophic mediators into extracellular 
vesicles (exosomes, microvesicles) (Doeppner, et al. 2015; Ophelders, 
et al. 2016). These extracellular vesicles cannot only transport 
proregenerative factors, but also mRNA and microRNA but even 
mitochondrial components over a long distance (Rani, et al. 2015; 
Yanez-Mo, et al. 2015). 
It is not yet clarified whether these trophic functions require MSC to 
home and engraft to the sites of injury as there are also indications that 
conditioned medium, extracellular vesicles or other shuttled factors 
have been functional (Gao, et al. 2014; Nagaishi, et al. 2016; Park, et 





diabetic complications has been shown (Lee, et al. 2006; Sordi, et al. 
2005). Tissue regeneration, revascularization and sustained 
normoglycemia were achieved. In NOD-SCID and STZ diabetic mice 
MSC injection restored glycemia by increasing β cell mass and 
promoting renal protection (increased proliferation, decreased 
apoptosis, increased levels of proregenerative factors, and anti-
inflammatory cytokines, decreased macrophage infiltration and 
oxidative stress damage) (Ezquer, et al. 2015; Ezquer, et al. 2008). 
Priming of MSC appears to even further improve these effects (Xu, et 
al. 2009). MSC, genetically-engineered to express VEGF or 
pancreatic-duodenal homeobox 1 (PDX-1), improved survival and 
reversed hyperglycemia. The effect, however, was only sustained when 
injecting VEGF-MSC and involved recovery of β cell mass (Milanesi, 
et al. 2012). 
In models of diabetic neuropathy, MSC have been shown to act via 
induction of neurotrophic factors, e.g. NGF and neurotrophin-3 (NT-
3). Both were significantly increased 2 weeks post-infusion, but no 
more 4 weeks post-infusion (Kim, et al. 2011). A recent study indicates 
that MSC injection in diabetic neuropathy has additional effects by 
reducing inflammatory cytokines, apoptosis, calcium and ROS levels 
(Oses, et al. 2017). 
To date, the mode trophic mode of action of, proangiogenic, MSCs 
appears paradoxal, in particular with respect to DR in which 
angiogenesis should be dampened or normalized instead of promoted. 
The caveat in this reasoning, is that MSCs secrete a plethora of 
paracrine factors, that partly have opposite functions, while MSCs may 
act to normalize aberrant microvasculature via juxtacrine mechanisms 
too (described in the next section). Nevertheless, a number of factors 





disease modalities may have adverse effects in DR. Many of these 
factors, in fact, are considered as biomarkers for DR and have been 
attributed to disease progression. VEGF, for instance, is a target of 
therapeutic interventions in DR. There is evidence that anti-VEGF 
antibodies (bevacizumab, Avastin or ranibizumab, Lucentis) have 
protective effects and can slow down disease progression (Li, et al. 
2017b; Martinez-Zapata, et al. 2014). These anti-VEGF-A antibodies 
recognize all isoforms of VEGF, although it might be advantageous in 
the future to target only those specific isoforms known to cause trouble. 
For instance, a recent study addressed the expression of the two 
isoforms of VEGF, VEGF165a and VEGF165b, considered to represent 
pro- or anti-angiogenic VEGF, and their receptors in plasma of patients 
with DR, with diabetes or controls (Paine, et al. 2017). With increasing 
disease stages, VEGF165a and VEGFR-2 concentrations were increased. 
A variety of other intravitreal growth factors, cytokines and 
chemokines have been attributed to disease progression and considered 
as potential biomarkers or even as therapeutic targets. However, it has 
to be taken into account that vitrectomy is only performed in only a 
minority of patients and mostly at severe disease stages and that thus 
samples might be contaminated with serum/plasma proteins, especially 
in severe disease stages (Abcouwer 2013). Similar to VEGF, further 
angiogenic factors such as angiopoietin-2 (Ang-2), osteopontin, PDGF, 
erythropoietin (EPO), stromal cell derived factor 1 (SDF-1) have been 
found to be increased, and vice versa anti-angiogenic factors decreased, 
such as pigment epithelium derived growth factor (PEDF), endostatin, 
angiostatin and tissue kallikrein (reviewed in (Abcouwer 2013)). A 
recent meta-analysis identified VEGF, IL6, IL8, EPO, PDGF-BB, NO, 
endothelin-1 (ET-1), monocyte chemotactic protein 1 (MCP-1), TGF-
β, and TNF-α to be increased in the vitreous of patients with 





decreased (McAuley, et al. 2014). In this meta-analysis, VEGF was the 
only biomarker which was able to significantly discriminate patients 
with and without nonproliferative DR. Since a variety of these 
molecules have dual functional roles, the may not only represent 
disease but also the attempt to regenerate injured tissue. IL6, for 
instance, is considered as proinflammatory molecule but it is known to 
orchestrate functions, not only in the immune system, but also in the 
nervous system. Here it can increase inflammation and thus tissue 
damage, but acting as neuropoietin it can also support neuronal 
regeneration (Suzuki, et al. 2009). 
Because DR is a multifactorial and multistep disease, protection or 
slow-down of progression requires a well-orchestrated milieu 
balancing intrinsic repair attempts against adverse stress events 
promoting injury. MSC are highly plastic and adapt their repertoire of 
secreted factors, to cues of the local microenvironment (Phinney 2007). 
Accordingly, these cells secret a variety of factors, which are 
considered to contribute to DR progression, MSC may assist to change 
track from a vicious cycle to a proregenerative response. 
MSC to act as pericytes 
Pericytes are cells that wrap around microvessels throughout the body 
and which are of mesodermal origin. Ever since the first light 
microscopy studies in the late 19th century, little has changed on this 
description. In a landmark publication, Zimmermann published 
detailed light microscopy studies on pericytes and their intimate 
contact with capillaries (Zimmermann 1923). Currently, the working 
definition of a pericyte is a (peri)vascular, basement membrane-
embedded cell (Sims 1986). In the microvasculature three types of 
contractile perivascular cell types, pericytes, smooth muscle cells and 





that can (trans)differentiate into each other and which may be derived 
from a common CD146+ endothelial precursor (Zimmerlin, et al. 
2013). This high plasticity and the lack of definitive pericyte markers, 
as well as rapid phenotypic changes in vitro, render ‘pericytes’ a 
heterogeneous population at best (reviewed in (Armulik, et al. 2011)). 
Pericyte loss is considered a key event in the initiation of 
vasoregression (Hammes 2005). Very recently it has been shown that 
selective pericyte loss is not enough to mediate blood retinal barrier 
(BRB) disintegration. However, loss of pericyte coverage sensitizes 
retinal vascular EC to VEGF-A. Via FOXO1 this leads to Ang-2 
upregulation and triggers a positive feedback loop as seen in the 
pathogenesis of DR (Park, et al. 2017a). 
MSC share several features with pericytes, such as their morphology 
and function but also their anatomic localization as perivascular cells. 
It was long debated which in situ origin MSC may have and where 
these are localized. Crisan et al. documented that in a magnitude of 
tissues MSC derive from a perivascular origin (Crisan, et al. 2008). 
These data suggest that pericytes might be the in vivo progenitor of 
MSC (Caplan 2008; Caplan 2017). Recent data however, challenge this 
idea. Guimarães-Camboa et al. used lineage tracing of 
pericytes/smooth muscle cells expressing the transcription factor 
Tbx18 to demonstrate that perivascular cells do not behave as tissue-
specific progenitors in various organs, neither in aging nor in 
pathological settings (Guimarães-Camboa, et al. 2017). Tbx18 cells 
kept their identity and failed to differentiate to other cell types. Sorted 
in vitro cultured Tbx18 pericytes, however, showed MSC potential, 
such as phenotype and differentiation potential. In line with this, a 
variety of data indicate that pericytes can be differentiated out of 





protocols from 20 reports (Xu, et al. 2017). The markers most 
commonly used to identify pericytes were PDGFR-β, alpha-smooth 
muscle actin (α-SMA), neural/glia antigen 2 (NG2), desmin and 
regulator of G-protein signaling 5 (RGS5) (Diaz-Flores, et al. 2009). 
However, expression patterns on pericytes in vivo can differ at different 
developmental stages and in different tissues and organs. Accordingly, 
a combination of phenotypic markers, perivascular location, 
morphology, and functionality shall be used to define pericyte identity. 
These are all animal-based results; thus, the translation to human 
clinical applications warrants caution. 
ASC have been shown to differentiate to pericytes in vitro and in vivo. 
Based on surface markers, the group of Bruno Peault classified adipose 
tissue derived MSC into two major groups: CD31- /CD45- /CD34+ 
/CD146- cells (adventitial stromal/stem cells [ASC]) and CD31- 
/CD45- /CD34- /CD146+ cells (pericytes [PCs]). Using single-cell 
quantitative polymerase chain reaction they recently showed that 
aldehyde dehydrogenase (ALDH) activity can identify subclasses. 
ALDHbright-ASC were classified as the most primitive cells, followed 
by ALDHdim-ASC, ALDHbright-PC and finally ALDHdim-PC as 
least primitive, suggesting ASC at the basis of the differentiation 
hierarchy (Hardy, et al. 2017; Herrmann, et al. 2016). Transcriptomic 
analysis of highly purified non-cultured adipose tissue derived cells 
support this notion that perivascular MSC are precursors of pericytes 
(da Silva Meirelles, et al. 2016). One study performed a direct 
comparison of MSC and pericytes (isolated based on CD34+, CD146+ 
expression from adipose tissue and bone marrow and retinal and 
placental pericytes. This comparison revealed reduced proliferative 
capacity of pericytes. MSC markers were comparable and highly 
expressed on all cell populations (CD44+CD90+CD73+CD105+ 





variable, CD146+NG-2+PDGFRβ+ on 1.3% and 3.6% of retinal and 
placental pericytes and 48% to 80% on bone marrow or adipose tissue-
derived MSC and pericytes. Interestingly, PDGFRβ expression 
appeared to be highly variant, but not discriminatory for MSC vs. 
pericytes (Herrmann, et al. 2016). This study showed higher osteogenic 
but slightly reduced adipogenic differentiation potential of the CD34+, 
CD146+ sorted pericytes from both tissues. Chondrogenic potential 
was only seen in cells from BM but reduced in the pericyte population. 
Angiogenic potential in a Matrigel tube formation assay did not reveal 
any differences between the different cells. 
The large phenotypical and functional overlap with pericytes renders 
MSC an ideal candidate in the cure and/or prevention of DR (Traktuev, 
et al. 2008). There are numerous indications that injected MSC acquire 
a perivascular fate within injured tissues. Examples for DR are given 
below. Of note, pericytes, also retinal pericytes, have been shown to 
exert immunomodulatory function such as MSC (Navarro, et al. 2016; 
Tu, et al. 2011). Loss of immunomodulatory functions by 
disappearance of pericytes may add to vasoregression by impaired 
control of immune responses (see below). 
MSC to restore the extracellular matrix 
It is well documented that hyperglycemia, e.g. AGE modification, 
leads to changes in the retina, including the extracellular matrix (ECM) 
composition, matrix metalloprotease activity and basement membrane 
thickening (Hammes, et al. 1996; Yang, et al. 2007). Resulting changes 
of interaction of EC and pericytes, as well as induced apoptosis, can 
lead to abnormal function, pericyte migration, endothelial cell 
apoptosis and finally increased permeability (Preissner, et al. 1997). 
Since pericytes and EC are important components of the neurovascular 





The basement membrane is mainly composed of laminin, collagen type 
IV, fibronectin as structural components and proteoglycans such as 
perlecan and nidogens 1 and 2. It allows cell attachment and binds 
growth factors. Especially the heparan sulfate attached platelet derived 
growth factor (PDGF) appears to be relevant for the maintenance of 
cell-cell/cell-matrix interaction. PDGF is required for the BRB 
formation by recruiting pericytes and inducing their maturation (Park, 
et al. 2017b). 
ECM degradation is required for vessel sprouting, thus there is a tight 
regulation of expression of matrix metalloproteases (MMPs) and their 
inhibitors (van Dijk, et al. 2015). In mesangial repair MSC have been 
shown to reverse the alterations of ECM proteins and by this contribute 
to repair (Herrera, et al. 2016). 
Furthermore, glycated matrix can trigger inflammation. AGEs are 
sensed by the receptor for advanced glycation endproducts (RAGE). 
RAGE activation results in pro-oxidant and pro-inflammatory 
pathways and an activation of the innate immune system additionally 
contributing to the vicious cycle of vasoregression (Zong, et al. 2010). 
In a hyperoxia-induced lung injury model, MSC reduced signs of 
damage, associated with reduced RAGE/NFkB expression and TNF-α 
secretion, suggesting an impact on RAGE/NFkB signaling (Tian, et al. 
2013). AGEs can affect MSC (Aikawa, et al. 2016; Kume, et al. 2005; 
Stolzing, et al. 2010). However, COMP-Ang, a chimeric form of 
Angiopoietin1 fused to the coiled-coil domain of rat cartilage 
oligomeric matrix protein, prevented negative effects of AGEs and 






MSC as scavengers of reactive oxygen species 
Molecular oxygen acquires oxidant property if an unpaired electron is 
excited and changes its spin. Several molecules and free radicals derive 
from the reduction of oxygen, these molecular modifications are 
defined as ROS (Liochev and Fridovich 1999). If the cellular metabolic 
pathways involved in ROS detoxification are impaired, oxidants 
indiscriminately react with proteins and DNA (Turrens 2003). Cellular 
oxidative stress may originate from mitochondria via dysfunction of 
the electron transport chain or from the cytoplasm via NADH-oxidases 
(Nox) among others. Pathways that further dysregulate ROS 
production include increased polyol pathway flux, increased AGE 
formation, and activation of protein kinase C (PKC) isoforms 
(Brownlee 2000). Diabetes causes ROS accumulation with serious 
complications (Giacco and Brownlee 2010) including DR (Guzman, et 
al. 2017; Kowluru and Chan 2007; Kowluru and Mishra 2015). 
Obviously, the reversal of either retinal ROS production or the 
scavenging by ROS neutralizing molecules has been put forward in 
therapeutic context. Hyperglycemia-induced ROS, via the TGF-β-
activated kinase 1 (TAK1) –NFκB signaling axis, also perpetuates 
inflammation in cells (Ajibade, et al. 2013; Hoesel and Schmid 2013; 
Morgan and Liu 2011). 
MSC are equipped with a full array of mechanisms that neutralize 
oxygen and nitrogen radicals. These include glutathione peroxidases 
(GPx1-3), thioredoxin reductases (TrxR1, TrxR2), and superoxide 
dismutases (SOD1, SOD2), as well as DNA repair systems (Ezquer, et 
al. 2014; Valle-Prieto and Conget 2010a). Several of these redox 
balancing systems, however, depend on co-factors e.g. 
supplementation of culture medium with selenium augments MSC’s 





protective mechanisms, ROS may promote apoptosis (Hajmousa, et al. 
2016) and senescence (Chen, et al. 2015; Jeong and Cho 2015; Ko, et 
al. 2012) of MSCs in vitro. ASC from obese mice have severe 
mitochondrial dysfunction and increased ROS production (Perez, et al. 
2015) which might compromise the use of ASC from adipose diabetics 
for cell therapy. NOX-induced ROS reduces the (longterm) 
proliferative capacity of ASC (Sela, et al. 2015). On the contrary, anti-
oxidant pathways e.g. regulated via Nuclear Factor E2-related factor 
(Nrf2) cross-talk with pro-inflammatory NFκB signaling which 
balances ROS responses in ASC (Chen, et al. 2016). Peterson and co-
workers, report that acute hypoxic exposure of pro-inflammatory-
primed (IFNγ) ASC, dramatically increased intracellular ROS, while 
longterm exposure render these ASC in a pro-angiogenic state 
(Peterson, et al. 2011). Hypoxic preconditioning alone also promotes 
survival of MSC in a ROS-dependent fashion (Valle-Prieto and Conget 
2010b). This suggests that ROS-based preconditioning of ASC is 
beneficial for cell therapy, provided the right timing and conditions are 
determined and selected. In fact, hypoxically preconditioned ASC, 
accompanied by increased intracellular ROS, promoted survival 
primary hepatocytes via extracellular matrix-derived signaling, more 
than via soluble trophic factors (Qin, et al. 2015). 
Yet, how does this affect the influence of MSC on exogenously 
produced ROS or on intracellular ROS production of target cells? For 
the past decade, results accumulated that MSC harbor anti-oxidative 
features in rodent models of diabetes, such as diabetic nephropathy, 
diabetic neuropathy and DR (Ezquer, et al. 2015; Fang, et al. 2012; Ho, 
et al. 2012; Lv, et al. 2014; Ren, et al. 2013; Sukpat, et al. 2013). For 
instance, conditioned medium from umbilical cord MSC (UC-MSC) 





superoxide dismutase, zinc-superoxide dismutase, manganese 
superoxide dismutase, glutathione peroxidase and catalase by ROS-
producing muscle cells (Park, et al. 2016). In addition, oxidative stress 
provoked by hyperglycemia did not compromise the glucose uptake 
and only partly abrogated mitochondrial functionality of ASC 
(Hajmousa, et al. 2016). Furthermore, ASC capacity to function as 
vascular supportive cells was maintained. One of the strategies that 
MSC acquire to modulate oxidative stress might involve mitochondria 
transfer to target cells (Melcher, et al. 2017). In this study, in vitro 
cultured fibroblasts deficient of mitochondrial complex one (CI) 
accepted MSC mitochondria. ROS could be further reduced by either 
treating MSC with TNF-α, or MSC conditioned medium. 
The aforementioned studies did not directly evaluate the ROS 
metabolism in MSC in vivo. Reports which address the balance of ROS 
guided by MSC injection in animal models affected by DR are lacking. 
Li and co-workers showed a first strategy to attenuate ROS during 
retinal ischemia. In this study, MSC were engineered to overexpress 
heme oxygenase-1 (HO-1), which catalyzes heme to biliverdin, free 
iron, and carbon monoxide (CO) and alleviates the oxidative stress. A 
reduction in apoptosis caused by the activation of antiapoptotic 
proteins Akt-1 and Bcl-2 was observed (Li, et al. 2017a). The 
intravitreal injection of ASC in the STZ-induced T1D mice suppressed 
oxidative damage in the retina, which indicates that ASC influence 
ROS levels directly or indirectly (Ezquer, et al. 2015). 
Overall these studies showed that MSC are capable to regulate ROS 
production in a variety of target cells. The molecular mechanisms 
comprise direct regulation of ROS with anti-oxidant enzymes, 
normalization of mitochondrial function, reprogramming of glucose 





upregulation of MAP kinase signaling. In general, suppression of ROS 
coincides with suppression of a pro-inflammatory status of cells, 
although it may occur that inflammation is suppressed while ROS is 
maintained. 
MSC to target inflammation 
Chronic low-grade inflammation (also called paraflammation) appears 
to be involved in the pathogenesis of DR, however it is most likely not 
involved in incipient stages of DR (Karlstetter, et al. 2015; Wang, et al. 
2014). Hyperglycemia and hypertension induce oxidative stress, 
apoptosis, fatty acid metabolism and AGE/RAGE interactions. 
Increased levels of pro-inflammatory mediators, such as IL1α, IL1β, 
IL6, IL8, MCP-1, TNFα, and IL18 and chemokines, such as CCL2, 
CCL5, CXCL8, CXCL10, and CXCL1 have been detected in the 
vitreous of patients with advanced DR and proliferative DR, correlated 
to increased VEGF concentrations (Murugeswari, et al. 2008; 
Wakabayashi, et al. 2010). Inflammasome activation has been 
observed both in patients with proliferative DR and in the STZ animal 
models (Capitao and Soares 2016; Chen, et al. 2017). Resulting 
macrophage/microglia activation and M1 polarization fosters 
endothelial, glial and neuronal stress and sometimes degeneration 
(Abcouwer 2011; Ma, et al. 2014). Modeling endothelial activation, in 
human umbilical vein endothelial cells, co-stimulated with 
hyperglycemia and high doses of palmitic acid, to mimic DR-
associated glucolipotoxicity, UC-MSCs suppressed inflammation (An, 
et al. 2016). Both NFκB activation was suppressed as well as 
downstream activation of glucolipotoxicity-related TNF-α-induced 
protein 6 (TSG-6). The endothelial phenotype appeared restored, 
because tube formation was normalized, but unexpectedly endothelial 





play a minor role for local activities, as they are typically not found as 
infiltrates. Nevertheless, there are some indications, that patients with 
advanced DR stages show changes in the balance of T helper cell 
cytokines in serum and vitreous. Furthermore, T cell infiltrates in 
vitreous of patients with proliferative DR have been observed (Capitao 
and Soares 2016). 
MSC have proven broad immunomodulatory potential in various 
disease entities involving inflammatory and immune processes. 
However, since inflammation and immune responses at different stages 
in the development and progression of DR may play a distinctive role, 
the functions of MSC in this respect remain open. As mentioned, 
animal models are limited in modeling all stages of the human disease 
and thus do not represent the late stage disease in humans. 
Nevertheless, we would like to speculate on possible contributions of 
MSC in inflammation and immune responses. 
MSC and microglia 
Microglia are the resident macrophages of the CNS in the retina. They 
become activated in the concourse of diabetes (Wang, et al. 2014). This 
has been observed both in humans and in animal models. Plasticity is 
a very well-known property of macrophages. In fact, they are able to 
respond to changes in their microenvironment polarizing towards an 
M1 or M2 phenotype. M1 macrophages are playing the major role in 
inflammation; producing pro-inflammatory cytokines and a large 
quantity of NO, and triggering the activation of the Th1 mediated 
immune response. On the contrary, M2 macrophages possess an 
immunosuppressive phenotype correlated to the production of anti-
inflammatory cytokines like IL-10 (Gordon and Martinez 2010; 
Mantovani, et al. 2002). It appears, that in early phases of DR, activated 





phenotype, whereas at later stages the balance changes towards pro-
inflammatory M1 phenotypes. Wang et al. identified CD74 as a 
microglia activation marker which increased upon both glucose and 
methylglyoxal administration in a rat model (Li and Lin 2012; Wang, 
et al. 2014). CD74 is involved in the formation and transport of 
MHC/HLA-class II molecules, and is thus important for antigen 
presentation. Furthermore, it acts as receptor for Macrophage 
Migration Inhibitory Factor (MIF). Recent data in glioma models 
suggest that tumor-secreted MIF acting on CD74-activated microglia 
promotes a shift towards M2 macrophages (Ghoochani, et al. 2016). 
So far there is no study published analyzing the interaction of MSC 
with retinal microglia in the context of DR. One study showed that 
MSC engineered to express CX3CL1 exert neuroprotective and 
immunomodulatory function in a model of light-induced retinal 
degeneration (Huang, et al. 2013). Here microglia activation and 
migration were reduced in MSC-transplanted animals. Modulation of 
microglia activation has also recently been shown by Jaimes et al. Here, 
BV-2, a murine microglia cell line, and primary murine brain microglia 
were cultured with microvesicles obtained from MSC supernatant. LPS 
induced activation of microglia was prevented (Jaimes, et al. 2017). 
This fits to own unpublished data analyzing the effect of human ASC 
supernatant on primary human macrophages (K. Widmanm, 
unpublished). We observed a clear reduction of M1 in favor of a M2 
polarization. An elegant study conducted by Melief et al. showed how 
Treg induction (see below) may be dependent on the skewing of 
monocytes toward a M2 phenotype. They observed that Treg formation 
was increased in MSC-PBMC cocultures more than MSC-CD4+ 
cocultures, suggesting the involvement of monocytes in Treg 
induction. Analyzing the monocyte fraction of cocultures they found 





secretion and 2) monocytes from cocultures have a decreased mRNA 
expression of pro-inflammatory cytokines with a concomitant increase 
in mRNA expression of anti-inflammatory cytokines and CCL18. 
CCL18 turned out to be key cytokine in driving Treg generation, 
suggesting that the modulation of monocytes towards an M2 phenotype 
may be a crucial mechanism in MSC mediated Treg formation (Melief, 
et al. 2013). 
All these observations found a surprisingly confirmation in a murine 
animal model of allo- and autoimmunity in the eye. Although it does 
not belong to the specific topic of this review, we briefly summarize 
these data as they maybe informative for future studies applying stem 
cells in DR considering immunogenicity of transplanted cells. In fact, 
Ko et al. demonstrated that intravenous injections of MSC were able to 
protect from rejection of corneal allotransplantation and from an 
experimental autoimmune uveitis (EAU). In the corneal 
allotransplantation model, MSC prevented histological abnormalities 
and reduced pro-inflammatory cytokines in the eye. Similarly, in EAU, 
MSC injection reduced IL2, IL1β, IL6 and TNF-α in the eyeball. A 
B220+CD11b+ monocyte population found in the lung as well as in 
blood, spleen and lymph nodes mediated these effects. In addition, 
increasing levels of Treg where found one day after MSC infusion, and 
lower level of Th1/Th17 cells were induced in coculture of 
B220+CD11b+/CD4+ T cells. Collectively these results suggest that 
monocytes, which were primed by the infusion of MSC, were able to 
promote Treg proliferation and inhibit the pro-inflammatory phenotype 
of T cells. More interestingly, intravenous infusion of MSC induced-
B220+CD11b+ cells were able to prevent corneal rejection and EAU 
as well, highlighting the fact that they are crucial in the MSC mediated 





MSC and T-cells 
As previously introduced, MSC affect a variety of immune cells and 
appear to regulate immune responses in favor of a pro-regenerative 
rather than an adverse injury-response. It is highly speculative whether 
the MSC effects on T cell responses may contribute to therapeutic 
efficacy in DR, nevertheless, we will summarize the known and 
provide possible links to DR. 
In diabetes there have been reports, that MSC can exert anti-diabetic 
effects by affecting T cells. An improvement in the Th1/Th2 balance, 
decreased Th17 and increased Treg numbers have been reported in 
models of T1D (Bassi, et al. 2012; Ezquer, et al. 2012; Favaro, et al. 
2014). Volarevic et al. have shown a disbalance of T-cell derived IL-1 
and its receptor antagonist (IL-1Rα) as a cause of β-cell impairment in 
T2D. In a mouse model, the β-cell damage has been ameliorated by 
MSC-derived IL1-Rα (Volarevic, et al. 2010). Whether MSC-mediated 
modulation of the T helper cell balance could be a MoA in DR has not 
been investigated yet. 
MSC exert a strong suppressive effect on T cell proliferation, when T 
cells are triggered by different mitogenic stimuli such as PHA or anti-
CD3/anti-CD28 monoclonal antibodies (Mohammadzadeh, et al. 2014; 
Nicola, et al. 2002; Yan, et al. 2014a). On the contrary, they seem to 
support their survival when T cells are in a quiescent state (Benvenuto, 
et al. 2007). Mechanisms that regulate the interaction with T cells still 
need elucidation; however, many studies revealed that both cell-cell 
interaction and production of soluble factors may drive MSC 
immunomodulation (Haddad and Saldanha-Araujo 2014). In co-culture 
with naïve or activated T cells, MSC inhibited T cell proliferation 
principally by soluble factors. In one study, MSC conditioned media 





caused cell arrest in G0/G1 phase. The major factors responsible for T 
cell energy were IL-10 and IDO (Yang, et al. 2009). Yan at al. reported 
MSC inhibition on activated T cells in both direct and indirect 
coculture system. Here, the axis PD-1/B7-H1 was partially involved in 
inducing T cell apoptosis, with a dispensable role of IL-10 and TGF-β 
in the up-regulation of PD-1 on T cells (Yan, et al. 2014b). 
Furthermore, MSC can affect the balance of T helper (Th) cell subsets 
Th1, Th2 and Th17 cells and can induce Treg cells (Maccario, et al. 
2005). Th cells have been classified into Th1 cells, which produce IL2 
and IFNγ and are involved in cellular immunity; Th2 cells which 
produce IL-4, IL-5 and IL-13 and are involved in humoral immunity; 
and Th17 cells producing the proinflammatory cytokine IL-17. Treg 
are commonly described as a CD4+CD25+Foxp3+ cells capable of 
suppressing other immune cells (von Boehmer 2005). They can 
originate from thymus as a mature subpopulation or be induced from a 
circulating naïve T cell population (Sakaguchi, et al. 2008). Treg 
formation seems to be triggered more by soluble factors than cell-cell 
interaction. A tight balance between Th1/Th2 and Th17/Treg has to be 
maintained for homeostasis (Zhang, et al. 2014). Generation of ASC-
induced functional Treg was observed in coculture by Engela et al. and 
resulted to be IL-2 pathway-dependent (Engela, et al. 2013). In another 
study, MSC derived PGE2 was involved in Treg generation, as a PGE2 
inhibitor resulted in reduced Fox-P3 mRNA expression in CD4+ T 
cells (English, et al. 2009). It has been shown that MSC are able to 
inhibit Th1 and Th17 differentiation, depending on the differentiation 
stage and coculture ratio (Luz-Crawford, et al. 2013).  High levels of 
PGE2, TGFβ and IL-10 were found in coculture of MSC with 





There are few indications that T cells may play a role in DR. There are 
no T cells in the retina, thus effects on T cells may be related to rather 
systemic (autoimmune) than local responses. Some studies report a 
dysregulated Th1/Th2/Th17/Treg balance in favor of a pro-
inflammatory Th1 and Th17 cytokine profile in serum and vitreous of 
patients with proliferative DR (Cao, et al. 2016; Takeuchi, et al. 2015). 
One study analyzed Th1/Th2 cytokines in the serum of 25 healthy 
subjects compared to 35 T2D patients without DR and 30 T2D patients 
with DR. In patients with DR the Th1 cytokines IL-2 and TNFα were 
strongly upregulated, even stronger in the T2D without DR group. Th2 
cytokines were lower in T2D patients with DR, whereas T2D patients 
without DR showed no difference to the control cohort (Cao, et al. 
2016). In another study, a pro-inflammatory skewed profile with 
expanded Th1/Th17 cells and reduced Treg has been observed. It 
correlated to an increased urine albumin:creatinine ratio indicative of 
diabetic nephropathy (Zhang, et al. 2014). In an experimental model of 
STZ-induced diabetes, blockade of IL-23, a cytokine critical for 
survival and proliferation of Th17 cells, significantly improved 
structure and tightness of the BRB (Xu, et al. 2015). However, the 
impact of these findings for human disease are unknown, as this model 
never develops proliferative DR and has also no relevant BRB 
disruption compared with humans.  
Interestingly Th1/Th2 cytokines have been related to angiogenesis, by 
either controlling it directly or indirectly by modulating other factors 
in the micromilieu (Naldini, et al. 2003). Pro-inflammatory Th1 
cytokines appear to be inhibitory to endothelial cell and vessel growth, 
whereas anti-inflammatory T cells appear to be positive regulators of 
angiogenesis. Since MSC have profound properties in restoring the 






MSC, autoantibodies and the complement system 
The DR-mediated cell degeneration can induce adaptive immune 
responses. For instance, auto-antibodies reactive against EC and 
pericytes have been detected in the serum of patients with diabetes and 
DR. This correlated to increased concentration of serum complement 
factors C3a and C5a, but not 4a. These autoantibodies conferred 
complement-mediated pericyte toxicity (Abcouwer 2013; McAuley, et 
al. 2014; Paine, et al. 2017). Antibody-injured pericytes were also 
affected in their efficacy to reduce T cell proliferation (Suzuki, et al. 
2009). Upon disease progression, and due to increased pericyte loss, 
pericyte-reactive autoantibodies become decreased (McAuley, et al. 
2014). In vitro, hyperglycemic culture increased the susceptibility of 
pericytes to become attacked. CD38, a known diabetes-associated 
autoantigen, was upregulated by IFNγ and TNFα and was involved in 
antibody-dependent pericyte damage (Suzuki, et al. 2009). 
Complement factors 3a and 5a are chemotactic for MSC and can recruit 
and retain MSC at sites of injury (Schraufstatter, et al. 2009). MSC 
constitutively secrete the important complement regulatory factor H 
and constitutively express the three complement regulatory receptors 
CD46, CD55 and CD59 (Li and Lin 2012; Tu, et al. 2010). Studies 
showed that MSC can prevent- via factor H- complement activation 
and cell damage (Li, et al. 2016; Tu, et al. 2010). However, despite 
expression of these regulatory factors, MSC per se can be targeted by 
the complement system once they are in contact with serum (Li and Lin 
2012; Li, et al. 2016). This has to be taken into account when planning 






MSC efficacy in DR 
Various adult cell therapies have been explored, i.e. CD34 
hematopoietic stem/progenitor cells, endothelial progenitor cells and 
MSC (Lois, et al. 2014; Park 2016). Animal models used to investigate 
the impact of cell therapy in the context of diabetic retinopathy are 
summarized in Table 2. 
Intravitreal administration of multipotent stromal cells of mesenchymal 
origin gave encouraging results for the treatment of early phase of DR 
(Rajashekhar 2014). Vascular leakage, apoptosis and inflammation 
were drastically downregulated. Ezquer et al. focused on the ROS-
induced damage to the neurovascular unit of the retina, to find that 
retinal ganglion cells death was attenuated and neurotrophic factors 
such as NGF, bFGF and GDNF increased when MSC were injected 
(Ezquer, et al. 2016). Interestingly, the ASC did not acquire neural-like 
or perivascular-like phenotypes. 
A similar localization pattern of ASC was also found in another study 
after intravitreal injection in oxygen-induced retinopathy (OIR) NOD-
SCID mice. In this study, DiI labeled ASC were localized alongside 
the central retinal microvasculature up to eight weeks after injection, 
adopting a pericyte-like perivascular location and wrapping around 
vessels. These cells were also positive for the pericytic markers NG2 
and alpha-SMA. ASC treatment pre and post induction of OIR reduced 
avascular areas in the retina, suggesting that even with the time 
dependent decrease of ASC, modulation of the retinal 
microenvironment with soluble/paracrine factors may mediate retinal 
microvessel protection. Of note, having established that ASC can 
acquire a pericytic phenotype and protect against OIR, the treatment 
was repeated on Akimba mice, recapitulating the findings of OIR mice 





Tassoni and coworkers addressed the potential risks associated with 
cell injection. They addressed retinal glial responses (graft-induced 
reactive gliosis) upon intravitreally injected rat BM-MSC (Tassoni, et 
al. 2015). Inflammation and extensive reactive gliosis driven by 
JAK/STAT3 and MAPK cascade were accompanied by macrophage 
infiltration and retinal detachment upon BM-MSC intravitreal 
transplantation. Müller cells expressing NGF receptor and 
neurotrophic tyrosine kinase receptor type 1 (TrkA) were observed in 
the retinas of rats transplanted with rBMSC. Factors downstream of 
NGF/TrkA signaling, such as p-PI3K, p-Akt and p-CREB, were also 
increased in Müller cells (Jian, et al. 2015). 
Cell therapy requires knowledge of the retinal pathological 
microenvironment prior to cells implantation to be able to ensure safety 
and efficacy. To this regard, the role of pericytes-EC interaction in the 
retina has been further elucidated. Partial depletion of pericytes 
resulted in a lack of spontaneous normalization of pericyte-EC 
associations in adult animals. Moreover, this caused an inflammatory 
response and macrophages infiltration, ultimately leading to a negative 
vascular damage loop via VEGF, PIGF and Ang-2 (Ogura, et al. 2017). 
This study suggests that hyperglycemia alone can initiate the 
progression of DR, however parallel pathological routes independently 
and irreversibly damage the retina. In line with this study, the role of 
ASC-EC communication has been linked to Notch signaling. 
Specifically, NOTCH2 is a transmembrane ligand which mediates 
ASC migration and their communication with EC (Terlizzi et al., 
submitted). Moreover, PDGFRβ downregulation was concomitant to 
NOTCH2 protein downregulation in ASC. Interestingly, 
hyperglycemia did not quantitatively influence the expression of Notch 
ligands and receptors in ASC. Modulation of evolutionary conserved 





proangiogenic capacity of ASC and maintain their regenerative 
capacity. 
In summary, MSC, specifically ASC exert at least a dual role in DR. 
First, these seem to resume a pericyte function, acquiring perivascular 
localization and endothelial cell enwrapping. By this, MSC/ASC 
appears to adopt pericytic regulatory functions, controlling survival 
and proliferation. Second, they secrete a variety of trophic factors 
which modulate the local adverse milieu by regulating oxidative stress, 
inflammation and integrity of the neurovascular unit. With the 
exception of the immunomodulatory function, the few animal data 
existing so far documented that MSC can exert the MoA, we proposed 
herein. Further studies are needed to elucidate efficacy (and MoA), and 
the safety/risk profile. Although it is expected that it takes its time to 
get enough knowledge to be able to move from bench to bedside, we 
think it is imperative to consider important questions: 
(1) optimal dose and  
(2) route of administration regarding the low survival of 
transplanted cells, 
(3) choice of animal models to model therapy-relevant DR stages 
(Fig. 1),  
(4) autologous or allogeneic approach due to impaired potency of 
MSCs from diabetes (see below),  
(5) safety versus risk of adverse events (cataract, accelerated 
disease progression due to induced and non-regulated 
angiogenesis, tumor formation, adverse differentiation), 
(6) identification of MoA (Fig. 2) and establishment of potency 
assays to predict therapeutic efficacy 






Table 2. Effects of injected mesenchymal and adipose stromal/stem cells 
in animal models relevant to diabetic retinopathy 
 






2, in 2 μL 
saline  
 
 - reduced retinal ganglion 
cells (RGCs) loss 
- do not differentiate into 
neural-like or 
perivascular-like cells 
- increased intraocular 
levels of neurotrophic 
factors 
- reduced retinal oxidative 
damage 






- loss of pericytes 











1 × 105 in 1 
µL 
-Extensive reactive gliosis 
and Inflammation 
- LCN2 production and 
activation of STAT3 and 
ERK in retinal Müller Glia 
NPDR 
- vasoregression 










0.5 to 1.5 uL 
of PBS and 
injected into 
the vitreous of 





- ASC migrated and 
integrated with the 
retinal vasculature 
- 16% reduction in 
avascular area 
- TGF-β1 enhanced 
hASC pericyte function 
PDR 
- retinal ischemia  
- proliferative 
vascular damage 







5 × 105 to 25× 
105   of GFP-
labeled ASC 
in 2 µL saline 
- improved neuronal 
function (ERG) 
- alleviated vascular 
leakage 
- alleviated apoptosis 
- ASC incorporated into 
the host vasculature 




1 × 105 CM-
Dil-labeled rat 
BMSC in 3 µl 
of PBS 




- Müller cell 
dedifferentiation via the 
NGF induced 
activation of PI3K and 
its 
association with the NGF 
receptor TrkA 





- ASC from diabetic 
sources have an 






- leaky capillaries 
. capillaries 
dropout 






Are ASC impaired by diabetes? 
The fact that ASC could be easily isolated in a large quantity and with 
non-invasive procedure, as well as a relatively easily expansion, makes 
them an impressive suitable candidate for autologous treatment options 
(Bieback, et al. 2012; Moonen, et al. 2012; Spiekman, et al. 2017; 
Wuchter, et al. 2015). However, in a specific disease context like 
diabetes, which is well known to affect the metabolism and adipose 
tissue, it is extremely important to assess whether these cells become 
affected by the disease. In fact, this would implicate a possible failure 
and/or impairment of the treatment. 
There are contradictory data. Some authors report similar functions and 
potency, whereas others identified differences between healthy and 
diabetic donors (Davies, et al. 2016; de Lima, et al. 2016; Ko, et al. 
2015; Yaochite, et al. 2016). Many studies investigated phenotypical 
and functional differences between healthy and diabetic ASC, mostly 
isolated from animal models (Cianfarani, et al. 2013; Cronk, et al. 
2015b; Rennert, et al. 2014). Cianfarani et al. observed differences in 
the expression of ASC markers in the stromal vascular fraction (SVF) 
isolated from diabetic mice fat pads, suggesting that a depletion of ASC 
can reflect their reduced survival and the functional impairment in 
secreting VEGF, HGF and IGF-1. Moreover, skin wounds treated with 
diabetic SVF resulted in reduced efficacies in wound healing compared 
to healthy SVF (Cianfarani, et al. 2013). 
Rennert et al. isolated ASC from inguinal fat pads of STZ C57BL mice 
and demonstrated their impaired angiogenic potential both in vitro and 
in vivo. In fact, ASC failed to induce tube like structures in coculture 
with HUVEC, although they assumed a perivascular position. This 
effect was also recapitulated in vivo, where gel plugs seeded with 





reduced levels of vascularization compared with healthy ASC. The 
authors also analyzed the composition of the freshly isolated SVF. As 
previously stated, they found a depletion of the global ASC population 
(here described as a CD45-CD31-CD34+ subpopulation of the SVF) 
(Rennert, et al. 2014). 
Similar findings regarding the impairment of the angiogenic potential 
were also assessed in model of DR (Cronk, et al. 2015a). While healthy 
ASC were able to improve vascular length density and numbers of 
branch points in the superficial vascular plexus of the retina of Akimba 
mice, diabetic ASC failed, although they reached the perivascular 
location. Analysis of cell bioenergetics revealed that healthy and 
diabetic ASC had a comparable rate of basal, ATP-dependent, 
uncoupled and non-mitochondrial respiration. 
Systems biologists contributed significantly to our understanding of 
metabolic shifts in diseases such as diabetes. Mardinoglu and Nielsen 
found that respiratory metabolism was significantly reduced in 
abdominal fat tissues of diabetic patients (Mardinoglu and Nielsen 
2015). Consequently, oxidated tryalglycerols were linked to slower 
dynamics of lipid molecules in the patients affected by diabetes. 
Mitochondrial pyruvate carrier 1 and 2 (MPC1-2) were strongly 
reduced in diabetic patients. Consequently, acetyl-CoA, central 
metabolite for biosynthesis of fatty acids, isoprenoids and involved in 
processes including protein prenylation and N-glycosylation, was also 
reduced (Pearce, et al. 2013). The authors concluded that limitation of 
condensation of oxaloacetate (OAA) which in turn, downregulated 
pyruvate and acetyl-CoA, interrupted tricarboxylic acid (TCA) cycle 





The prolonged exposure of ASC to hyperglycemia and the 
consequences caused by the associated oxidative stress, formation of 
ROS and AGEs such as inflammation likely contribute to their 
dysfunction such as their disturbed protective capacity in angiogenesis. 
Although, the underlying mechanisms are poorly understood, 
dysfunctional ASC from diabetics could be partially normalized by 
augmenting their capacity to clear AGEs i.e. via genetical modification 
with methylglyoxal-metabolizing enzyme glyoxalase-1 (GLO-1). 
Introduction of GLO-1 augmented the viability, migration and 
proangiogenic capacity of ASCs from diabetics. Moreover, in an STZ 
BALB/c mice model of limb ischemia, Glo-1 expressing ASC restored 
blood reperfusion, with an overall effect comparable to healthy ASC 
(Peng, et al. 2017). 
The alternative to an autologous setting is allogeneic MSCs. In a 
variety of clinical settings, MSCs are derived from allogeneic donors 
(without HLA-matching), mostly based on logistic reasons, rarely 
based on better efficacy (Ankrum, et al. 2014). In a variety of 
preclinical experiments, human cells have been applied to animal 
models of DR with signs of efficacy. In these models, no signs of 
alloreactivity/xenoreactivity have been reported so far. Since MSC 
application in DR in general is still in its infancy, safety aspects have 
to be well defined first before discussing autologous versus allogeneic 
use and HLA-matching or mismatching. As for a proper timing, very 
early DR preferentially needs systemic rather than local administration, 
with a safety profile in the range comparable to general antidiabetic and 
antihypertensive drugs, while routes of administration may change 
with disease progression (Griffin, et al. 2016). Other aspects such as 
the use of autologous versus allogeneic use and HLA-mis/-matching 





The future of cell therapy? 
As example of novel concepts, the next generation approaches may 
involve differentiation of cells before transplantation into the retina, as 
shown for age-related macular degeneration (AMD) (Kuriyan, et al. 
2017). Embryonic stem cells (ESC) differentiated to a cone phenotype 
survived and matured within a model of advanced retinal degeneration. 
Cell differentiation involved a controlled inhibition of Notch pathway 
to enhance cone differentiation. Inhibition or activation of specific 
signaling proteins involved in MSC differentiation might hold the key 
to effective cell-therapy. For example, retinal cells derived from hESC, 
migrate, settle and, differentiate into mice retinas. (Lamba, et al. 2009). 
Furthermore, hESC-derived retinae have been demonstrated to engraft 
and matured in two different primate models of retinal degeneration 
(Shirai, et al. 2016). A similar concept, but different approach, seeds 
mouse induced pluripotent stem cells (miPSCs) cultured in a 3D retinal 
tissue in vitro (Assawachananont, et al. 2014). Subsequent to 
transplantation into the sub-retinal space, iPSCs were able to 
reconstruct the outer nuclear layer of the retina in an advanced model 
of retinal degeneration. However, another study that combined the 
transplantation of human retinal pericytes (hRPCs) and human BM-
MSC in a rat model of retinal degeneration, showed great 
improvements in the overall health of the retinas. Integration and 
migration of both transplants increased compared to single cells 
transplantation. Importantly, activation of microglia and the gliosis of 
Müller cells were suppressed indicating an effective 
immunomodulatory effect (Qu, et al. 2017). 
Both human and murine autologous cells used for transplantation have 
been reported to selectively differentiate and integrate in the retinal 





demonstrated that human iPSC can generate retina-specific cell types, 
setting the bases for studying molecular mechanisms involved in cell-
differentiation (Meyer, et al. 2009). 
Besides this targeted differentiation, other approaches investigate 
whether local cell injection is needed or whether systemic infusion 
followed by local homing or even systemic effects may be efficacious. 
In other disease entities, conditioned medium or extracellular 
vesicles/exosomes were as efficient as direct cell injections (Marote, et 
al. 2016). Intraperitoneal infusion was able to prevent experimentally 
induced autoimmune uveitis by altering the Th1/Th17 response (Oh, et 
al. 2014). 
Clinical trials 
To date, investigations of MSC therapy in patients with DR are 
missing. There are a few cell therapy trials investigating intravitreal 
cell injections. A phase I clinical trial to assess the feasibility and safety 
of intravitreal injection of autologous CD34+ BM-cells is currently 
enrolling participants (NCT01736059). A first-in-human study to 
examine the safety of an intravitreal injection of autologous BM-MSC 
has been published recently (Satarian, et al. 2017). The patients in this 
study had advanced retinitis pigmentosa and were treated with 106 BM-
MSC per 0.1 ml behind the limbus in the phakic and pseudophakic 
eyes. This pilot resulted in a temporary improvement in perception of 
light. Three months later, fibrous tissue proliferation was observed with 
a tractional retinal detachment. Since biopsy could not be obtained 
from patients, MSC were transplanted in mice to investigate the shift 
in the cellular microenvironment provoked by the MSC implantation. 
The authors reported no detection of MSC after ten months. They 
concluded that MSC lead to macrophage infiltration and retinal folding 





used for injection to a complementary study (Kuriyan, et al. 2017). 
Although the number of ASC injected was not reported, 60-ml of 
liposuction aspiration was processed to isolate the stem cells. The 
resulted pellet was resuspended in platelet-rich plasma and 
immediately used for intravitreal injection in both eyes. The patients in 
this study had severe visual loss as well as hemorrhagic retinopathy and 
retinal detachment. The authors concluded that such a complication had 
to be analyzed from the point of view of cells’ preparation rather than 
the injection procedure. Because of these negative results from these 
early clinical trials, cell-therapy research is in need of information with 
regard to safety for human trials. In this respect, several clinical trials 
are to be initiated (NCT03011541, NCT01920867, NCT01736059). 
Furthermore, animal models capable of assessing efficacy and risk 
profile need to be established and careful studies need to be performed, 
controlling for benefits versus risks. 
It also has to be taken into account at which disease stage therapy shall 
be undertaken in terms of a benefit-to-risk assessment. Currently, 
patients at advanced disease stage receive intravitreal drug injections 
to slow down progression and prevent vision loss. Accordingly, the 
benefit-to-risk assessment has to weigh the risk of adverse events 
versus the beneficial effect preventing vision loss. MSC-based cell 
therapy, however, based on the MoA we summarized above, can be 
considered as an early treatment option to entirely prevent or delay DR 
onset and progression to pathological end stages. Here the benefit-to-
risk assessment is not yet weighing against vision loss. Accordingly, 
an extremely careful risk-to-benefit assessment is required, based on 






To date, MSC belong to the most intensely investigated cell types for 
cell-based therapies. Due to their diverse - and admittedly still 
incompletely understood – MoAs (Fig. 2), the efficacy of MSCs is 
challenged in various randomized clinical trials to treat a plethora of 
diseases. Overall, these trials are phase I safety trials and report that the 
use of MSCs is safe. Efficacy, nevertheless, remains to be documented. 
MSC-based therapy for eye diseases is still in its infancy. Preclinical 
data suggest beneficial effects in retinopathy, including DR. As 
mentioned before, more data are needed to be able to perform a 
thorough risk-to-benefit assessment prior to clinical trials and in bench-
to-bedside-and-back approaches. Only these will help to understand 
potential risks and relevant, and possibly disease-stage dependent 
mode of action. 
This review discusses the potential mode of action of MSC in DR (Fig. 
2), highlights that a delicate interplay between the different cell types 
and the diabetic microenvironment needs to be taken into 
consideration, and requires appropriate models.  
In DR, there is preclinical evidence that MSC 
1) adopt pericyte functions regulation vascular proliferation and 
survival,  
2) secrete trophic factors in favor of a proregenerative shift within 
the micromilieu,  
3) reduce oxidative stress.  
The regulation of immune/inflammatory responses to expand favorable 
phenotypes (M2 macrophages and Treg respectively) has not been 






The complexity of diabetic microvascular complications, together with 
the limitation of animal models and, not yet proven safety for human 
clinical trials, requires a careful analysis from fundamental biology to 
patients’ susceptibility to improve cell therapy. 
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